FLT3 and acute myeloid leukemia: Several FLT3 tyrosine kinase inhibitors (TKIs) have been developed to target the aberrantly activated FLT3 receptor and to suppress constitutive tyrosine phosphorylation in FLT3-ITD AML [3, 4].